Litcius/Paper detail

Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status

Alexander Peikert, Parag Goyal, Muthiah Vaduganathan, Brian Claggett, Ian J. Kulac, Zi Michael Miao, Orly Vardeny, Mikhail Kosiborod, Akshay S. Desai, Pardeep S. Jhund, Carolyn S.P. Lam, Silvio E. Inzucchi, Felipe A. Martínez, Rudolf A. de Boer, Adrian F. Hernandez, Sanjiv J. Shah, Magnus Petersson, Anna Maria Langkilde, John J.V. McMurray, Scott D. Solomon

2023JACC Heart Failure26 citationsDOIOpen Access PDF

Topics & Concepts

MedicineEjection fractionPolypharmacyDapagliflozinHeart failureCardiologyInternal medicineIntensive care medicineDiabetes mellitusEndocrinologyType 2 diabetesDiabetes Treatment and ManagementCardiovascular Function and Risk FactorsHeart Failure Treatment and Management
Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status | Litcius